2013 AMPLIFY TRIAL Oral Apixaban for the Treatment of Acute Venous Thromboembolism double-blind, multicenter, randomized controlled trial IM Objective: To determine if apixaban is non-inferior to conventional therapy with LMWH in patients with pulmonary embolism or proximal deep venous thrombosis … Read More
PE
![](https://www.visualmed.org/wp-content/uploads/2023/03/AMPLIFY-trial.jpg)
![](https://www.visualmed.org/wp-content/uploads/2022/12/CANARY-trial.jpg)
CANARY Trial Summary: Cath vs AC in PE
2022 CANARY TRIAL Catheter-directed thrombolysis vs anticoagulation in patients with acute intermediate-high-risk pulmonary embolism parallel, open-label, randomized controlled trial Objective: To assess the effectiveness of catheter-directed thrombolysis (CCDT) compared with anticoagulation among intermediate- to high-risk individuals with acute pulmonary embolism … Read More
![](https://www.visualmed.org/wp-content/uploads/2022/11/ADAM-VTE.jpg)
ADAM VTE Trial Summary: Apixaban in Cancer-associated VTE
2019 ADAM VTE TRIAL Apixaban and dalteparin in active malignancy-associated venous thromboembolism multicenter, randomized, open-label superiority trial 287 patients 0 Objective: To study side effects of and compare apixaban and dalteparin in reducing blood clots in patients with cancer-related VTE. … Read More
![](https://www.visualmed.org/wp-content/uploads/2022/09/AXIOMATIC-TKR-TRIAL.jpg)
AXIOMATIC-TKR Trial Summary: Milvexian for the Prevention of VTE
2022 AXIOMATIC-TKR TRIAL Milvexian for the prevention of Venous thromboembolism Parallel-group, Open-label, randomized controlled trial Objective: To compare the efficacy & safety of milvexian and enoxaparin in patients undergoing elective knee arthroplasty 1242 patients INCLUSION CRITERIA: Patients undergoing unilateral total … Read More